Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

186.44 -3.50 (-1.84%)
Streaming Delayed Price Updated: 9:51 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Analyst Expectations for Ligand Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Why Are Novan Shares Nosediving Today? ↗
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to  
Via Benzinga
News headline image
3 Stocks That Smart Investors Should Be Flocking to Now ↗
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
Via InvestorPlace
News headline image
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
News headline image
Recap: Ligand Pharmaceuticals Q1 Earnings ↗
 
Via Benzinga
News headline image
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗
 
Via Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Earnings Scheduled For February 17, 2022 ↗
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
News headline image
Earnings Scheduled For February 22, 2023 ↗
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
News headline image
Ligand Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
News headline image
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says ↗
Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. 
Via Benzinga
News headline image
Ligand Pharma Issues Mixed Guidance For FY23 ↗
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... 
Via Benzinga
News headline image
Earnings Outlook For Ligand Pharmaceuticals ↗
Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million. 
Via Benzinga
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients ↗
 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Ligand Pharmaceuticals: Q2 Earnings Insights ↗
  Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals... 
Via Benzinga
News headline image
Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗
Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger ↗
Ligand Pharmaceuticals Inc (NASDAQ: LGND)  
Via Benzinga
News headline image
Tough Slogging Ahead for Investors, Diversification is Important ↗
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
News headline image
Recap: Ligand Pharmaceuticals Q4 Earnings ↗
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
News headline image
Meme Stock Breakdown ↗
There have been plenty of market happenings and themes in 2021 but perhaps one of the more intriguing ones was the recurring bouts of meme stock mania. 
Via Talk Markets
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.